NanoGroup
Private Company
Total funding raised: $6.7M
Overview
NanoGroup is a publicly traded Polish biotech firm developing a diversified pipeline based on two core nanotechnology platforms: the NanOX system for organ preservation and transport of respiratory gases, and polysaccharide nanoparticle conjugates for targeted oncology. The company is in a pre-revenue, pre-clinical stage, actively raising capital and progressing multiple programs toward key 2026/2027 milestones. Its strategy involves building a group of subsidiaries (NanoSanguis, NanoVelos) to advance its platforms while also making strategic investments, such as in Auxilius Pharma's cardiovascular drug program.
Technology Platform
Two core platforms: 1) NanOX platform for synthetic transport of respiratory gases, applied to organ perfusion fluids and devices, and targeting a blood substitute. 2) Polysaccharide-based nanoparticle/conjugate platform for targeted drug delivery, initially focused on dextran conjugates for oncology.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In organ perfusion, NanoGroup competes with established hypothermic storage solutions and newer normothermic perfusion systems from companies like TransMedics and XVIVO. In targeted drug delivery, it faces numerous biotech and pharma companies developing antibody-drug conjugates (ADCs) and other nanoparticle therapies. Its blood substitute ambition enters a field with a long history of high-profile failures, though a few candidates remain in development globally.